AdrenoMed Stresses Personalized Therapies for Septic Shock

AdrenoMed AG, a company focused on vascular integrity, underscores the need for personalized therapies in septic shock amid the new 2026 Surviving Sepsis Campaign Guidelines and the U.S. SEPSIS Act. These developments highlight the persistent therapeutic gaps in septic shock treatment, emphasizing the survival benefit of evidence-based, personalized approaches.

AdrenoMed is preparing its investigational therapy, enibarcimab, for a pivotal, biomarker-guided Phase III clinical trial. Enibarcimab, a non-blocking monoclonal antibody, aims to stabilize vascular integrity and improve survival in septic shock patients, targeting those identified by specific biomarkers.

The company has aligned with regulatory bodies, including the FDA and EMA, and highlights the need for funding to advance enibarcimab into late-stage development. The U.S. SEPSIS Act signals sepsis's priority as a public health issue, bolstering the case for financial support of innovative treatments like enibarcimab.